Form 4: Oaktree Acquisition Corp. III Life Sciences: Major Shareholders Adjust Holdings After Over-Allotment Option Exercise

Oaktree Acquisition Holdings III LS, LLC and related entities adjust their holdings in Oaktree Acquisition Corp. III Life Sciences following the partial exercise of an over-allotment option by underwriters.

Summary

• Oaktree Acquisition Holdings III LS, LLC and affiliated entities have filed a Form 4 detailing changes in their beneficial ownership of Oaktree Acquisition Corp. III Life Sciences (OACC) securities.
• These changes are related to the partial exercise of an over-allotment option by the underwriters of OACC's initial public offering.
• Holdings purchased 33,981 additional private placement units at $10.00 per unit in connection with the partial over-allotment option exercise.
• Each unit consists of one Class A ordinary share and one-fifth of one warrant.
• Holdings forfeited 231,492 Class B ordinary shares at no cost due to the partial exercise of the over-allotment option.
• Following these transactions, Holdings directly owns 583,981 Class A ordinary shares, 4,799,758 Class A ordinary shares issuable upon conversion of Class B ordinary shares, and 116,796 private placement warrants.
• The filing also includes information about the indirect ownership and control of these securities by various Oaktree and Brookfield entities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document primarily reports transactions related to the over-allotment option exercise, which is a standard procedure. There are no explicit positive or negative statements about the company's future prospects.

Negatives

• Oaktree Acquisition Holdings III LS, LLC forfeited 231,492 Class B ordinary shares, indicating a reduction in potential future ownership.

Risks

• The value of the private placement warrants is dependent on the future performance of Oaktree Acquisition Corp. III Life Sciences and its ability to complete a business combination.
• The conversion of Class B ordinary shares into Class A ordinary shares is contingent upon the completion of the issuer's initial business combination.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but it references the potential conversion of Class B shares to Class A shares upon the completion of a business combination.

Industry Context

This filing is typical for special purpose acquisition companies (SPACs) following their IPO and the exercise of over-allotment options. It reflects adjustments in ownership structure as the company moves towards identifying and completing a business combination.

Comparison to Industry Standards

• SPACs like Oaktree Acquisition Corp. III Life Sciences often issue founder shares (Class B) and private placement units to sponsors and related parties.
• The conversion of Class B shares to Class A shares upon a business combination is a standard feature in SPAC structures.
• The forfeiture of shares due to partial exercise of over-allotment options is also a common occurrence in SPAC transactions.
• Comparable companies include other SPACs in the life sciences sector, such as CM Life Science Investment Corp. and Decibel Therapeutics, which have similar ownership structures and transaction dynamics.

Related Party Transactions

• The purchase of private placement units by Oaktree Acquisition Holdings III LS, LLC is a related party transaction.

Stakeholder Impact

• The transactions described in the Form 4 may have a minor impact on shareholders due to the change in ownership percentages.
• The potential exercise of private placement warrants could dilute existing shareholders.

Next Steps

• The company will likely continue to seek a business combination target.
• The holders of the private placement warrants may exercise them in the future, potentially increasing the number of outstanding Class A ordinary shares.

Key Dates